ADC Therapeutics Announces Abstracts Accepted for : vimarsan

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include...

Related Keywords

California , United States , New Jersey , Switzerland , San Diego , London , City Of , United Kingdom , China , San Francisco Bay , Chinese , American , Loncastuximab Tesirine , Nicole Riley , Juan Pablo Alderuccio , Lausanne Biop , Mohamed Zaki , Eugenia Litz , European Commission , Company Annual Report On Form , European Union , Exchange Commission , Drug Administration , Mitsubishi Tanabe Pharma Corporation , Duration Loncastuximab Tesirine , San Diego Convention Center On , Linkedin , European Medicines Agency , American Society Of Hematology , American Society , Annual Meeting , Chief Medical Officer , Limited Duration Loncastuximab Tesirine , Refractory Follicular Lymphoma , Manchester Grand Hyatt San Diego , Grand Hall , Sustained Circulating Tumor , Refractory Diffuse Largeb Cell , Global Study , Novel Agents , Adolescent Relapsed , Refractoryb Cell Non Hodgkin Lymphoma , Prospective Therapeutic Trials , Manageable Safety Profile , Heavily Pretreated Chinese Patients , Diffuse Largeb Cell Lymphoma , Hallsg H , San Diego Convention Center , San Francisco Bay Area , Private Securities Litigation Reform Act , Swedish Orphan Biovitrum , European Economic Area , Infrastructure Investment , Jobs Act , Healthcare Royalty Management , Blue Owl , Annual Report , Nyse Adct , Adc Therapeutics Sa , Antibody Drug Conjugate , Biotechnology , Biotech , Dlbcl , Lymphoma ,